Analysis of BRCA1 germline variants (exons 5, 11 and 20) in breast cancer families from Libya

References

• Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, & Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca A Cancer J Clinicians. 2024;10(3): Advance online publication. 229–14. doi: 10.3322/caac.21834
   Google Scholar
• Arnold M, Morgan E, Rumgay H, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast [Internet]. 2022;66(August):15–23. Available from 10.1016/j.breast.2022.08.010
   PubMedGoogle Scholar
• Feizi H, Alizadeh M, Nejadghaderi SA, et al. The burden of chronic obstructive pulmonary disease and its attributable risk factors in the Middle East and North Africa region, 1990–2019. Respir Res [Internet]. 2022;23(1):1–15. Available from 10.1186/s12931-022-02242-z
   PubMed Web of Science ®Google Scholar
• Elbiad O, Laraqui A, El BF, Mounjid C, Lamsisi M, Bajjou T, et al. Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa. BMC Cancer [Internet]. 2022;22(1):1–19. Available from doi: 10.1186/s12885-022-09181-4
   PubMed Web of Science ®Google Scholar
• Wang SM. A global perspective on the ethnic-specific BRCA variation and its implication in clinical application. J Natl Cancer Cent. 2023;3(1):14–20. doi: 10.1016/j.jncc.2022.12.001
   Google Scholar
• Mighri N, Hamdi Y, Boujemaa M, et al. Identification of Novel BRCA1 and RAD50 mutations associated with breast cancer predisposition in Tunisian patients. Front Genet. 2020;11(November). doi: 10.3389/fgene.2020.552971
   PubMedGoogle Scholar
• Fourati A, Louchez M, Fournier J, et al. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or. Bull Cancer. 2014;101(11):E36–E40. doi: 10.1684/bdc.2014.2049
   PubMed Web of Science ®Google Scholar
• Abdulrashid K, Alhussaini N, Ahmed W, et al. Prevalence of BRCA mutations among hereditary breast and/or ovarian cancer patients in Arab countries: systematic review and meta-analysis. BMC Cancer. 2019;19(1):1–12. doi: 10.1186/s12885-019-5463-1
   PubMedGoogle Scholar
• Rotimi SO, Rotimi OA, Salhia B. A review of cancer genetics and genomics studies in Africa. Front Oncol. 2021;10(February):1–24. doi: 10.3389/fonc.2020.606400
   Google Scholar
• Hamdi Y, Mighri N, Boujemaa M, et al. Identification of eleven novel BRCA mutations in Tunisia: Impact on the clinical management of BRCA related cancers. Front Oncol. 2021;11(August). doi: 10.3389/fonc.2021.674965
   Google Scholar
• Ayed-Guerfali D B, Kridis-Rejab W B, Ammous-Boukhris N, Ayadi W, Charfi S, Khanfir A, et al. Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia. J Transl Med [Internet]. 2021;19(1):1–10. Available from doi: 10.1186/s12967-021-02772-y
   PubMed Web of Science ®Google Scholar
• Abulkhair O, Al BM, Makram O, et al. Prevalence of BRCA1 and BRCA2 mutations among high-risk Saudi patients with breast cancer. J Glob Oncol. 2018;2018(4):1–9. doi: 10.1200/JGO.18.00066
   Google Scholar
• Wang SM. Journal of the National cancer center a global perspective on the ethnic-specific BRCA variation and its implication in clinical application. J Nat Cancer Cent. 2023;3(1):14–20. doi: 10.1016/j.jncc.2022.12.001
   Google Scholar
• Triki-Fendri S, Sánchez-Diz P, Rey-González D, et al. Paternal lineages in Libya inferred from Y-chromosome haplogroups. Am J Phys Anthropol. 2015;157(2):242–251. doi: 10.1002/ajpa.22705
   PubMed Web of Science ®Google Scholar
• Najem F. N15: pHD Tribe, Islam and State in Libya ; analytical study of the roots. London, UK: University of Westminster; 2004.
   Google Scholar
• Clark SL, Rodriguez AM, Snyder RR, Hankins GDV, Boehning D. Structure-function of the tumor suppressor BRCA1. Comput Struct Biotechnol J [Internet]. 2012;1(1):e201204005. Available from doi: 10.5936/csbj.201204005
   PubMedGoogle Scholar
• Ismail T, Alzneika S, Riguene E, et al. BRCA1 and its Vulnerable C-Terminal BRCT domain: Structure, function, genetic mutations and links to Diagnosis and treatment of breast and ovarian cancer. Pharmaceuticals. 2024;17(3):333. doi: 10.3390/ph17030333
   Web of Science ®Google Scholar
• NCCN clinical practice guidelines in oncology (NCCN Guidelines). Genetic/familial high-risk assessment: breast, ovarian and Pancreatic. National Comprehensive Cancer Network. Version 2.2022. [citied 2022 Mar 9] Available from: https://www.melbournebreastcancersurgery.com.au/wp-content/themes/ypo-theme/pdf/nccn-clinical-practice-genetic.pdf
   Google Scholar
• Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St gallen international expert consensus on the primary therapy of early breast cancer 2011. Annals Oncology. 2011;2011(8):1736–1747. doi: 10.1093/annonc/mdr304
   Google Scholar
• AJCC Cancer Staging Manual. AJCC cancer staging manual. 2010.
   Google Scholar
• Mahfoudh W, Bouaouina N, Ben AS, et al. Hereditary breast cancer in Middle Eastern and North African (MENA) populations: Identification of novel, recurrent and founder BRCA1 mutations in the Tunisian population. Mol Biol Rep. 2012;39(2):1037–1046. doi: 10.1007/s11033-011-0829-8
   PubMed Web of Science ®Google Scholar
• Dines JN, Shirts BH, Slavin TP, et al. Systematic misclassification of missense variants in BRCA1 and BRCA2 “coldspots. Genet Med. 2020;22(5):825–830. doi: 10.1038/s41436-019-0740-6
   PubMed Web of Science ®Google Scholar
• Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med [Internet]. 2015;17(5):405–424. Available from doi: 10.1038/gim.2015.30
   PubMed Web of Science ®Google Scholar
• Hamdi Y, Mighri N, Boujemaa M, et al. Identification of eleven novel BRCA mutations in Tunisia: Impact on the clinical management of BRCA related cancers. Front Oncol. 2021 Aug;11:3181. doi: 10.3389/fonc.2021.674965
   Web of Science ®Google Scholar
• Rentzsch P, Witten D, Cooper GM, et al. CADD: Predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 2019;47(D1):D886–94. doi: 10.1093/nar/gky1016
   PubMed Web of Science ®Google Scholar
• Sokolenko AP, Sultanova LV, Stepanov IA, et al. Strong founder effect for BRCA1 c.3629_3630delAG pathogenic variant in Chechen patients with breast or ovarian cancer. Cancer Med. 2023;12(3):3167–3171. doi: 10.1002/cam4.5159
   PubMed Web of Science ®Google Scholar
• Laraqui A, Uhrhammer N, Lahlou-Amine I, et al. Mutation screening of the BRCA1 gene in early onset and familial breast/ovarian cancer in Moroccan population. Int J Med Sci. 2012;10(1):60–67. doi: 10.7150/ijms.5014
   PubMed Web of Science ®Google Scholar
• Henouda S, Bensalem A, Reggad R, et al. Contribution of BRCA1 and BRCA2 germline mutations to early Algerian breast cancer. Dis Markers. 2016;2016:1–7. doi: 10.1155/2016/7869095
   Web of Science ®Google Scholar
• Troudi W, Uhrhammer N, Ben RK, et al. Complete mutation screening and haplotype characterization of BRCA1 gene in Tunisian patients with familial breast cancer. Cancer Biomarkers. 2008;4(1):11–18. doi: 10.3233/CBM-2008-4102
   PubMed Web of Science ®Google Scholar
• Cherbal F, Bakour R, Adane S, et al. BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families. Dis Markers. 2010 Jan;28(6):377–384. doi: 10.1155/2010/585278
   PubMed Web of Science ®Google Scholar
• El KM, Diakite B, Hamzi K, et al. Screening of exon 11 of BRCA1 gene using the high resolution melting approach for diagnosis in Moroccan breast cancer patients. BMC Cancer. 2015;15(1):1–5. doi: 10.1186/s12885-015-1040-4
   PubMedGoogle Scholar
• Purnomosari D, Pals G, Wahyono A, et al. BRCA1 and BRCA2 germline mutation analysis in the Indonesian population. Breast Cancer Res Treat. 2007;106(2):297–304. doi: 10.1007/s10549-006-9493-4
   PubMed Web of Science ®Google Scholar
• Blay P, Santamaría I, Pitiot AS, et al. Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain). BMC Cancer. 2013;13(1):1–10. doi: 10.1186/1471-2407-13-243
   PubMedGoogle Scholar
• Mehemmai C, Cherbal F, Hamdi Y. BRCA1 and BRCA2 germline mutation analysis in hereditary breast/ovarian cancer families from the aures region (Eastern Algeria. Pathol Oncol Res. 2020;26(2):715–726. doi: 10.1007/s12253-019-00586-4
   PubMed Web of Science ®Google Scholar